The Health Service Medical Supplies (Costs) Act 2017 (c. 23) is an Act of the Parliament of the United Kingdom.
| Act of Parliament | |
 | |
| Long title | An Act to make provision in connection with controlling the cost of health service medicines and other medical supplies; to make provision in connection with the provision of pricing and other information by those manufacturing, distributing or supplying those medicines and supplies, and other related products, and the disclosure of that information; and for connected purposes. |
|---|---|
| Citation | 2017 c. 23 |
| Introduced by | Jeremy Hunt (Commons) Lord O’Shaughnessy (Lords) |
| Territorial extent | England and Wales, Scotland and Northern Ireland |
| Dates | |
| Royal assent | 27 April 2017 |
| History of passage through Parliament | |
| Text of statute as originally enacted | |
| Revised text of statute as amended | |
It provides that pharmaceutical companies can be compelled to reduce the price of a generic medicine or introduce other controls on branded products in cases where charges are “unreasonable”.[1]
References
edit- ^ "New legislation passed to prevent excessive price hiking of generic drugs". Pharmaceutical Journal. 3 May 2017. Retrieved 30 May 2017.
External links
edit- Text of the Health Service Medical Supplies (Costs) Act 2017 as in force today (including any amendments) within the United Kingdom, from legislation.gov.uk.